Ultra-Hypofractionated Radiotherapy for Early-Stage Glottic Cancer: Real-World Data From a Single Center.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 40170367.
- Also identified by DOI 10.1002/hed.28139 and PMC identifier 12338007.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
In recent years, smaller-volume radiotherapy has attracted attention. It appears to be a safe and effective treatment for glottic laryngeal cancer. This study evaluated the results of ultra-hypofractionated radiotherapy for early glottic laryngeal cancer in unfit patients. This retrospective study analyzed 22 patients diagnosed with early glottic cancer between June 2017 and January 2021. The involved vocal cord was treated with 35-42.5 Gy in 5 fractions. On a 59-month median follow-up, the 5-year overall survival and local control rate were 68.2% and 94.7%, respectively. However, the 5-year larynx preservation rate was 89.7%. Chondronecrosis was observed in one patient (4.5%), and soft tissue necrosis in one patient (4.5%). PTV<sub>D98</sub> (> 41.08 Gy) was found to be statistically significant in surgery-needed events (HR: 22.4, 95% CI: 1.9-252.1, p = 0.01). Single-cord ultra-hypofractionated radiotherapy appears to be an effective treatment for local control. However, the risk of radionecrosis is higher at doses above 41.08 Gy.
Medical subject headings
- Laryngeal Neoplasms
- Glottis
- Radiation Dose Hypofractionation